India, June 18 -- Shares of Aptevo Therapeutics Inc. (APVO) gained 240% on Wednesday morning after the clinical-stage biotechnology company announced new clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig, its first-in-class CD123 x CD3 bispecific antibody, in combination with standard-of-care venetoclax and azacitidine (ven/aza) for newly diagnosed patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy.
APVO is currently trading at $9.64, up $6.82 or 241.84%, on a volume of 92 million shares, above average volume of 283 thousand, on the Nasdaq. The stock opened its trading at $6.17 after closing Tuesday at $2.82. The stock has traded between $2.81 and $485.44 in the past 52-week peri...